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Abstract Vitronectin (VN) and plasminogen activator inhibi-
tor-1 (PAI-1) have important functional interactions: VN sta-
bilises the protease inhibitory activity of PAI-1 and PAI-1 in-
hibits binding of adhesion receptors to VN. Having previously
mapped the PAI-1 binding area for VN, we have now con-
structed a PAI-1 variant, R103A-M112A-Q125A, without mea-
surable a⁄nity to VN, but with full protease inhibitory activity
and endocytosis receptor binding. As a tool for evaluating the
physiological and pathophysiological functions of the PAI-1^
VN interaction, our new variant is far superior to the previously
widely used PAI-1 variant Q125K, which we have found pos-
sesses an only about 10-fold reduced a⁄nity to VN.
- 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Plasminogen activator inhibitor-1 (PAI-1) is a mammalian
MrV50 000 extracellular protein. Mice with a disrupted PAI-
1 gene grow to adulthood and are fertile, but display a mild
hyper¢brinolytic phenotype with a decreased tendency to
thrombosis (for a review, see [1]). Accordingly, PAI-1 is a
fast and speci¢c inhibitor of the serine protease tissue-type
plasminogen activator, a key ¢brinolytic enzyme. PAI-1 is
also a fast and speci¢c inhibitor of the serine protease uroki-
nase-type plasminogen activator (uPA), which is implicated in
physiological and pathophysiological tissue remodelling (for a
review, see [2]).
PAI-1 belongs to the serpin class of protease inhibitors. The
serpin inhibitory mechanism begins with the protease attack-
ing the P1^P1P bond in the serpin reactive centre loop (RCL),
but at the enzyme^acyl intermediate stage, the N-terminal
part of the RCL inserts into a central L-sheet A, pulls the
protease to the opposite pole of the serpin, distorts it, and
halts its completion of the catalytic cycle. The energy needed
for protease distortion stems from stabilisation of the serpin
in the ‘relaxed’ conformation with the inserted RCL, as com-
pared to the ‘stressed’, unstable active conformation with the
surface-exposed RCL (for reviews, see [1,3]). PAI-1 can also
assume the inactive, relaxed, so-called latent state in which the
intact RCL is inserted into L-sheet A [4]. During RCL inser-
tion, the £exible joint region (K-helices E and F, L-strands 1A
and 2A, residues 95^145) lateral to the L-sheet A also changes
conformation (for a review, see [1]).
Some of the biological functions of PAI-1 seem to be re-
lated to interactions with molecules other than plasminogen
activators. First, stressed, but not relaxed, PAI-1 binds with
high a⁄nity to the MrV75 000 extracellular matrix and blood
plasma glycoprotein vitronectin (VN) and is thereby protected
against latency transition (for a review, see [1]) and inactiva-
tion by organo-chemical ligands, including 4,4P-dianilino-1,1P-
bisnaphthyl-5,5P-disulfonic acid (bis-ANS) [5,6]. Moreover,
active PAI-1 acts anti-adhesively by competing with integrins
and the uPA receptor (uPAR) for binding to VN (for a re-
view, see [1]). Second, complexes of plasminogen activators
and PAI-1 bind to endocytosis receptors of the low-density
lipoprotein receptor family including LRP. This binding is a
mechanism for clearing the complexes from the extracellular
space, but may also activate intracellular signaling pathways
(for a review, see [7]). PAI-1 variants speci¢cally inactivated
with respect to each of the speci¢c molecular interactions are
needed in order to sort out the biological functions of each
interaction.
VN binds to the £exible joint region of PAI-1. In the pio-
neering work by Lawrence et al. [8], screening of PAI-1 var-
iants produced by random mutagenesis was used to show that
the substitutions L118P and Q125K resulted in reduced VN
binding. A later report suggested implication of residues 116^
120 in VN binding [9]. Investigations with the less accurate
methods of antibody competition [10] and PAI-1^PAI-2 chi-
meras [11] also pointed towards the £exible joint region of
PAI-1. Using a novel strategy, based on identi¢cation of ami-
no acid (aa) residues necessary for VN protection of PAI-1
against inactivation by bis-ANS, we de¢ned 10 aa residues
forming a VN binding surface in the £exible joint region
[12]. The subsequently published X-ray crystal structure anal-
ysis of the complex between PAI-1 and the N-terminal 44 aa
somatomedin B domain of VN [13] was in full agreement with
these results. We have now constructed a PAI-1 variant with-
out measurable a⁄nity to VN, but with full ability to inhibit
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plasminogen activators and to interact with endocytosis recep-
tors.
2. Materials and methods
2.1. Materials
PAI-1 wild type (wt) and mutants were expressed by and puri¢ed
from Escherichia coli [12] or human HEK293T cells [14]. The PAI-1
aa numbering system used was based on the determination of the N-
terminal sequence of the protein as S1-A2-V3-H4-H5T [15]. Human
multimeric VN was from BD Biosciences (Franklin Lakes, NJ, USA).
Human uPA was from Wakamoto Pharmaceuticals (Tokyo, Japan).
uPA was inactivated with diisopropyl £uorophosphate (DFP) [16].
uPAR C-terminally truncated after D277 (soluble uPAR) was a
kind gift from Gunilla H$yer-Hansen, Finsen Laboratory [17].
Mab-2 is a previously described monoclonal antibody against PAI-1
[18^20]. Bis-ANS was from Molecular Probes (Eugene, OR, USA).
RPMI 1640 cell culture medium and foetal bovine serum (FBS) were
from Cambrex, BioWhittaker Europe (Belgium). S-2444 (pyro-Glu-
Gly-Arg-p-nitroanilide) was from Chromogenix (Mo«lndal, Sweden).
Phorbol 12-myristate 13-acetate (PMA) was from Sigma (St. Louis,
MO, USA).
2.2. PAI-1 activity measurements
The speci¢c inhibitory activities of PAI-1 wt and mutants were
measured as before [12]. To determine the IC50 values for bis-ANS
neutralisation of PAI-1, the speci¢c inhibitory activities of PAI-1,
without VN or preincubated with VN at concentrations of about 20
WM, were determined in the presence of several concentrations of bis-
ANS. The IC50 values were determined as the bis-ANS concentration
halving the speci¢c inhibitory activity [12]. To measure the rate of
latency transition, samples were withdrawn from solutions with 450
nM PAI-1, with or without 450 nM VN, for measurement of speci¢c
inhibitory activity after di¡erent time periods of incubation at 37‡C.
The latency transition half-lives were calculated from semi-logarithmic
plots of speci¢c inhibitory activity versus time. To evaluate Mab-2
neutralisation of PAI-1, the speci¢c inhibitory activity of PAI-1, with-
out VN or preincubated with VN at concentrations of about 20 WM,
was measured at di¡erent Mab-2 concentrations. Second-order rate
constants were determined as described [21].
2.3. Binding of uPA^PAI-1 complex to LRP
The binding of [125I]uPA^PAI-1 complex to LRP immobilised on
the solid phase of microtitre plates was measured as described [16],
using PAI-1 wt and mutants expressed by HEK293T cells [14], and a
[125I]uPA^PAI-1 complex concentration of 20 pM.
2.4. Solid-phase VN^PAI-1 binding assay
VN was coated onto the solid phase of Maxisorb microtitre plates
(Nunc, Roskilde, Denmark), using 100 Wl 0.5 Wg/ml VN in 50 mM
NaHCO3, pH 9.6, per well and incubation overnight at 4‡C. The wells
were blocked with 2% skim milk powder in phosphate-bu¡ered saline
(PBS). Aliquots of 100 Wl of PBS were added to the wells, with PAI-1
in concentrations between 250 nM and 3 pM, followed by 1 h incu-
bation at room temperature. The relative amounts of PAI-1 bound to
the solid phase were estimated with a layer of rabbit polyclonal anti-
PAI-1 antibodies, a layer of peroxidase-conjugated swine anti-rabbit
IgG, and a peroxidase reaction. The VN a⁄nity of the respective PAI-
1 variants relative to that of PAI-1 wt was calculated as the ratios
between the concentrations of variant and wt giving the same signal.
2.5. Binding analysis by surface plasmon resonance (SPR)
All analyses were performed with a BIACORE X1 instrument,
using a CM51 chip blocked with ethanolamine as reference in £ow
cell 2. To analyse the binding of PAI-1 variants to VN, a CM51 chip
was coated with 50 nM VN in 10 mM Na-acetate, pH 5.0, by a
standard amine coupling protocol until a density of approximately
2400 response units (RU) or approximately 33 fmol was accumulated
on the chip. Eighty Wl of PAI-1 wt or variants were injected in con-
centrations of 7, 10 and 14 nM at a £ow rate of 20 Wl/min. To elute
the remaining PAI-1 after each round of injection, 10 mM glycine-
HCl, pH 2.0 was injected until the baseline level was reached again.
Kd values were estimated from the association and dissociation rates,
using the software provided with the BIACORE X1 instrument, as-
suming 1:1 stoichiometry.
To analyse the uPAR^VN binding, a CM51 chip was coated with
soluble uPAR (0.5 WM in 10 mM Na-acetate, pH 4.5) by a standard
amine coupling protocol until approximately 2300 RU or approxi-
mately 40 fmol were accumulated on the chip. The immobilised
uPAR was kept saturated with DFP-inactivated uPA by constantly
using a running bu¡er (10 mM HEPES, 140 mM NaCl, 3 mM EDTA,
pH 7.4) supplemented with 12 pM DFP-inactivated uPA and by in-
jecting 50 Wl 100 nM DFP-inactivated uPA before each experiment.
For each experiment, VN was injected to saturation of the immobi-
lised uPAR (50 Wl 200 nM VN, corresponding to approximately 500
RU being immobilised), followed by running bu¡er for 400 s. Fifty Wl
of PAI-1 wt or mutants, in the concentration range of 1^200 nM, were
then injected, and the SPR signal from the chip followed for 280 s.
Between experiments, any VN remaining on the chip was eluted with
50 Wl 200 nM PAI-1 wt. A £ow rate of 10 Wl/min was used through-
out.
2.6. Binding of U937 cells to VN
[125I]VN was prepared as previously described [22]. U937 cells were
cultured in RPMI 1640 with 10% FBS. Cells (106/ml) were incubated
with PMA (160 nM) for 20 h. Adherent cells were scraped o¡ the disc
with a rubber policeman. The cells were washed with RPMI 1640
supplemented with 0.02% bovine serum albumin. [125I]VN was incu-
bated for 90 min on ice with or without PAI-1 additions as indicated
for each experiment, followed by incubation with 1U105 cells/ml on
ice for 90 min with a ¢nal [125I]VN concentration of 10 pM. Cells
were washed and harvested by centrifugation in a microfuge (12 000
rpm, 3.5 min) in the presence of 20% sucrose and the amount of cell-
associated [125I]VN in the pellet quanti¢ed in a Q counter. The
amounts of bound [125I]VN were corrected for non-speci¢c binding,
i.e. the binding with 10 pM [125I]VN plus 10 nM non-radioactive VN.
3. Results and discussion
To localise the VN binding area of PAI-1, we previously
constructed about 40 variants of PAI-1 with alanine substitu-
tions in the £exible joint region. Many of these had a reduced
speci¢c inhibitory activity, due to an increased tendency to
substrate behaviour or an increased fraction of the PAI-1
molecules being in a latent state. A direct VN^PAI-1 binding
assay would therefore give misleading results, as any relaxed
form of PAI-1 has a low a⁄nity to VN. We therefore chose
an alternative approach, measuring the interaction of VN with
only the fraction of active PAI-1 in the preparations. VN
protects PAI-1 wt against bis-ANS inactivation, and we
were able to show that alanine substitutions of F100, R103,
M112, K124, Q125, I137, D140, and W141 led to an only
partial protection against bis-ANS [12] (Table 1), strongly
suggesting that these residues form a VN binding surface on
PAI-1.
However, some of the variants in fact had a speci¢c inhib-
itory activity and a latency transition rate that were indistin-
guishable from those of PAI-1 wt. This was true for, among
others, PAI-1 R103A, PAI-1 M112A, and PAI-1 Q125A. In
order to obtain a variant with a complete lack of VN a⁄nity,
but otherwise normal, we combined these three substitutions
into one molecule. The triple substitution R103A-M112A-
Q125A led to a PAI-1 variant that did not di¡er signi¢cantly
from PAI-1 wt with respect to speci¢c inhibitory activity (Ta-
ble 1), latency transition rate (Table 1), second-order rate
constant for the uPA^PAI-1 reaction (data not shown), or
binding of uPA^PAI-1-complex to LRP (Fig. 1). But the tri-
ple mutant completely lacked the ability to be protected
against bis-ANS by VN (Table 1) and it had a more than
3000-fold reduced a⁄nity for VN as compared to the PAI-1
wt in an ELISA-type binding assay (Table 1). In contrast,
introduction of each mutation individually into PAI-1 led to
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an only slightly reduced VN binding, and a PAI-1 variant
widely used as a non-VN binder, Q125K [8], had an only
about three-fold reduced binding to VN in this assay (Table
1). In addition, we used SPR analysis to determine the Kd
values for the binding of PAI-1 wt and PAI-1 Q125K to
immobilised VN. We found values of 0.22V 0.2 nM (n=4)
and 2.8V 1.4 nM (n=5) for PAI-1 wt and PAI-1 Q125K,
respectively. Thus, PAI-1 Q125K has an at least 10-fold re-
duced a⁄nity compared to PAI-1 wt in this assay. The Kd
value for PAI-1 R103A-M112A-Q125A could not be deter-
mined in this assay as only unspeci¢c binding to the VN-
coated chip was detected (Fig. 2).
We next characterised the triple mutant and PAI-1 Q125K
with respect to a number of previously observed PAI-1^VN
interactions. First, VN delayed the latency transition of PAI-1
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Fig. 1. Analysis of binding of uPA^PAI-1 complex to LRP. Binding
of the indicated PAI-1 variants, expressed in HEK293T cells, in
complex with [125I]uPA to immobilised LRP was measured in a sol-
id-phase assay. Incubations without PAI-1 or in the presence of 10
mM EDTA were included as controls. The concentrations of
[125I]uPA^PAI-1 complex or [125I]uPA were 20 pM. The binding is
expressed relative to that of [125I]uPA in complex with PAI-1 wt.
Fig. 2. Analysis of binding of PAI-1 variants to VN by SPR. Ap-
proximately 33 fmol of VN was coupled to a CM51 BIACORE
chip. At time zero, 14 nM of the indicated PAI-1 variants, ex-
pressed in E. coli, were applied to the chip for 240 s. The time point
for end of injection is indicated by black arrows. Each of the ex-
periments shown is a typical one out of a total of three. Note that
the signal for PAI-1 R103A-M112A-Q125A declines before the in-
jections stops.
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Q125K in a manner indistinguishable from that of PAI-1 wt,
while the latency transition of the triple mutant was not af-
fected by VN (Table 1). Second, we previously demonstrated
that VN potentiates the inactivation of PAI-1 by the mono-
clonal antibody Mab-2. In the absence of VN, Mab-2 is a
weak inactivator of PAI-1 while in the presence of VN,
PAI-1 is inactivated by nM concentrations of Mab-2 [19,20].
The susceptibility of PAI-1 Q125K to Mab-2 was identical to
that of PAI-1 wt in the absence and presence of VN, but the
susceptibility of the triple mutant to Mab-2 was completely
una¡ected by VN (Fig. 3). Third, we measured the ability of
the PAI-1 variants to compete with uPAR for binding to VN
by SPR analysis. uPAR was immobilised covalently on a
BIACORE1 chip, and a complex between uPAR, DFP-inac-
tivated uPA, and VN assembled on the chip. uPA increases
the a⁄nity of uPAR to VN (for a review, see [1]). DFP-in-
activated uPA was used to avoid uPA^PAI-1 interaction. Ex-
posure of the uPAR^uPA^VN complex to PAI-1 wt led to
dissociation of VN from the complex, with a rate increasing in
the PAI-1 concentration range of 5^50 nM. PAI-1 Q125K
also caused dissociation of VN, although about ¢ve-fold high-
er concentrations were needed to achieve the same dissocia-
tion rate as with PAI-1 wt. In contrast, 200 nM PAI-1
R103A-M112A-Q125A did not cause measurable dissociation
of VN from the complex (Fig. 4). PAI-1 did not interfere with
the binding of DFP-inactivated uPA to uPAR on the chip
(data not shown).
Furthermore, we measured the ability of the PAI-1 variants
to inhibit the binding of U937 cells to VN, which is mediated
by uPAR [23]. The binding of [125I]VN to U937 cells could be
totally inhibited by su⁄ciently high concentrations of PAI-1
wt or PAI-1 Q125K. The concentrations causing half maximal
inhibition was very close to the Kd values determined by SPR
analysis. In contrast, PAI-1 R103A-M112A-Q125A did not
measurably inhibit the binding in concentrations up to 30
nM (Fig. 5).
In conclusion, we have constructed a triple mutant of PAI-1
without measurable a⁄nity to VN, but indistinguishable from
PAI-1 wt with respect to the interaction with plasminogen
activators and LRP. In assays testing several di¡erent func-
tional consequences of the PAI-1^VN binding, the triple mu-
tant did not respond measurably to VN. In contrast, while
Q125K did have a signi¢cantly reduced a⁄nity to VN, the
reduction was not large enough to render it unresponsive to
VN in all respects. In fact, in assays with the highest PAI-1
concentrations, it was indistinguishable from wt. The new
Fig. 3. E¡ect of VN on inactivation of PAI-1 by Mab-2. The ¢gure
shows the speci¢c inhibitory activities, relative to that of control, of
the indicated combinations of PAI-1 variants and VN, at the indi-
cated concentrations of Mab-2. All PAI-1 variants were expressed
in E. coli. Means and S.D. of triple determinations are indicated.
Fig. 4. Analysis of PAI-1 competition with uPAR for VN binding
by SPR. Approximately 40 fmol of soluble uPAR was coupled to a
CM51 BIACORE chip. The immobilised uPAR was saturated with
DFP-inactivated uPA and VN. At time zero, the indicated concen-
trations of the indicated PAI-1 variants, expressed in E. coli, were
applied to the chip. The initial increase in material bound to the
chip after application of PAI-1 presumably occurs because some of
the units of the multimeric VN on the chip are not engaged with
uPAR and thus free to bind PAI-1. Each of the experiments shown
is a typical one out of a total of three.
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variant therefore represents an important and reliable tool for
evaluating molecular aspects as well as physiological and
pathophysiological functions of the PAI-1^VN interaction.
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Fig. 5. PAI-1 inhibition of uPAR-mediated VN binding to U937
cells. The ¢gure shows the relative binding of 10 pM [125I]VN to
U937 cells in the presence of the indicated PAI-1 variants, expressed
in E. coli, in the indicated concentrations. Means and S.D. of triple
determinations are indicated.
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